Join the MoonLake Immunotherapeutics (MLTX) Securities Class Action Lawsuit

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against MoonLake Immunotherapeutics (MLTX).

If you purchased or otherwise acquired MoonLake Immunotherapeutics securities between March 10, 2024 and September 29, 2025, you may be eligible to join this class action lawsuit and seek compensation for your losses.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases.

The company’s lead product candidate, sonelokimab, is a Nanobody designed to treat conditions such as hidradenitis suppurativa (HS), a chronic skin disorder.

The Allegations

The class action lawsuit alleges that MoonLake and certain senior executives made false and misleading statements to investors about the clinical advantages of its only drug candidate, sonelokimab, and the benefits of its Nanobody structure.

According to the complaint, MoonLake made these claims during investor events and public statements beginning with its R&D Day on March 10, 2024, where the company described sonelokimab as being able to do things that monoclonal antibodies could not and emphasized its smaller size and tissue penetration.

Similar statements were allegedly repeated in a press release on November 7, 2024 (which did not name BIMZELX), in which management said the molecular advantages of the Nanobody translated into higher clinical responses and provided ample opportunity for differentiation versus competitors. The complaint alleges these representations were false because both sonelokimab and BIMZELX (a competitor) target the same inflammatory cytokines, IL-17A and IL-17F, and the Nanobody structure did not provide a superior clinical benefit.

When MoonLake announced 16-week results from its Phase 3 VELA program on September 28, 2025, only one of the two trials achieved statistical significance, and the drug failed to demonstrate competitive efficacy relative to BIMZELX.

The next trading day, September 29, 2025, MoonLake’s stock price fell $55.75 per share, or nearly 90%, closing at $6.24, wiping out billions in market value.

Important Dates

• Class period: March 10, 2024 to September 29, 2025
• Complaint filed: October 15, 2025
• Lead plaintiff deadline: December 15, 2025

Your Rights and Next Steps

Investors who purchased or otherwise acquired MoonLake Immunotherapeutics securities during the class period have important legal rights. These investors may be eligible to join the class action lawsuit as lead plaintiffs or class members. The lead plaintiff is the investor or group of investors appointed by the court to represent the interests of all class members.

Serving as lead plaintiff is not required to share in any potential recovery, but it allows investors to play a greater role in directing the litigation.

To be considered for the lead plaintiff role, investors must act before the deadline of December 15, 2025. Those who do not seek appointment may still be eligible to recover compensation if the lawsuit is successful.

Attorneys are available to answer investor inquiries, review trading records, and assist in evaluating potential claims. By participating in the class action, shareholders may be able to recover losses incurred as a result of the alleged securities fraud.

You May Be Entitled to Compensation

If you invested in MoonLake Immunotherapeutics during the class period and experienced financial losses following the company’s disclosures, you may be entitled to compensation.

To find out if you qualify and to take the next step in joining the lawsuit, complete the below form.